Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome

  • 67 Accesses

Abstract

Purpose of Review

This review summarizes our current knowledge on type 2 diabetes mellitus (T2DM) and glucose metabolism alterations in Prader-Willi syndrome (PWS), the most common syndromic cause of obesity, and serves as a guide for future research and current best practice.

Recent Findings

Diabetes occurs in 10–25% of PWS patients, usually in adulthood. Severe obesity is a significant risk factor for developing of T2DM in PWS. Paradoxically, despite severe obesity, a relative hypoinsulinemia, without the expected insulin resistance, is frequently observed in PWS. The majority of PWS subjects with T2DM are asymptomatic and diabetes-related complications are infrequent. Long-term growth hormone therapy does not adversely influence glucose homeostasis in all ages, if weight gain does not occur.

Summary

Early intervention to prevent obesity and the regular monitoring of glucose levels are recommended in PWS subjects. However, further studies are required to better understand the physiopathological mechanisms of T2DM in these patients.

This is a preview of subscription content, log in to check access.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.

    •• Butler MG, Miller JL, Forster JL. Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15 (4):207-44. https://doi.org/10.2174/1573396315666190716120925. A very recent and complete update on appropriate medical management, and best practice treatment approaches of Prader-Willi syndrome.

  2. 2.

    Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Investig. 2015;38(12):1249–63. https://doi.org/10.1007/s40618-015-0312-9.

  3. 3.

    Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14:10–26.

  4. 4.

    Crinò A, Di Giorgio G, Livieri C, et al. A survey on Prader-Willi syndrome in the Italian population: prevalence of historical and clinical signs. J Pediatr Endocrinol Metab. 2009;22(10):883–93.

  5. 5.

    Jauregi J, Laurier V, Copet P, Tauber M, Thuilleaux D. Behavioral profile of adults with Prader-Willi syndrome: correlations with individual and environmental variables. J Neurodev Disord. 2013 Aug 6;5(1):18. https://doi.org/10.1186/1866-1955-5-18.

  6. 6.

    Muscogiuri G, Formoso G, Pugliese G, Ruggeri RM, Scarano E. Colao a; RESTARE. Prader- Willi syndrome: an uptodate on endocrine and metabolic complications. Rev Endocr Metab Disord. 2019;20(2):239–50. https://doi.org/10.1007/s11154-019-09502-2.

  7. 7.

    • Duis J, van Wattum PJ, Scheimann A, Salehi P, Brokamp E, Fairbrother L, et al. A multidisciplinary approach to the clinical management of Prader-Willi syndrome. Mol Genet Genomic Med. 2019;7(3):e514. https://doi.org/10.1002/mgg3.514. This article takes into consideration the multidisciplinary care model for an optimal clinical management of PWS patients and emphasize the development of a “Center of Excellence” for these patients.

  8. 8.

    • Irizarry KA, Miller M, Freemark M, Haqq AM. Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Pediatr Infect Dis. 2016;63(1):47–77. This paper reports an overview on metabolic studies and glucose omeostasis in PWS and takes into consideration the current standard therapies and new therapeutic approaches in PWS.

  9. 9.

    Crinò A, Fintini D, Bocchini S, Grugni G. Obesity management in Prader-Willi syndrome: current perspectives. Diabetes Metab Syndr Obes. 2018;11:579–93.

  10. 10.

    • Tauber M, Coupaye M, Diene G, Molinas C, Valette M, Beauloye V. Prader-Willi syndrome: A model for understanding the ghrelin system. J Neuroendocrinol. 2019;31(7):e12728. https://doi.org/10.1111/jne.12728. Findings from this review provide recent data on the ghrelin dysfunction in PWS and discuss therapeutic perspectives targeting the ghrelin system in PWS.

  11. 11.

    Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155A:1040–9.

  12. 12.

    Dimitropoulos A, Schultz RT. Food-related neural circuitry in Prader-Willi syndrome: response to high- versus low-calorie foods. J Autism Dev Disord. 2008;38(9):1642–53. https://doi.org/10.1007/s10803-008-0546-x.

  13. 13.

    Zhang Y, Zhao H, Qiu S, Tian J, Wen X, Miller JL, et al. Altered functional brain networks in Prader-Willi syndrome. NMR Biomed. 2013 Jun;26(6):622–9. https://doi.org/10.1002/nbm.2900.

  14. 14.

    Pujol J, Blanco-Hinojo L, Esteba-Castillo S, Caixàs A, Harrison BJ, Bueno M, et al. Anomalous basal ganglia connectivity and obsessive-compulsive behaviour in patients with Prader-Willi syndrome. J Psychiatry Neurosci. 2016 Jun;41(4):261–71.

  15. 15.

    Xu M, Zhang Y, von Deneen KM, Zhu H, Gao JH. Brain structural alterations in obese children with and without Prader-Willi syndrome. Hum Brain Mapp. 2017 Aug;38(8):4228–38. https://doi.org/10.1002/hbm.23660.

  16. 16.

    Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, et al. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab. 2001;86:4330–8.

  17. 17.

    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, et al. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome. Growth Hormon IGF Res. 2010 Jun;20(3):179–84. https://doi.org/10.1016/j.ghir.2009.12.004.

  18. 18.

    Bedogni G, Grugni G, Tringali G, Marazzi N, Sartorio A. Does segmental body composition differ in women with Prader-Willi syndrome compared to women with essential obesity? J Endocrinol Investig. 2015 Sep;38(9):957–61. https://doi.org/10.1007/s40618-015-0266-y.

  19. 19.

    Tanaka Y, Abe Y, Oto Y, Itabashi H, Shiraishi M, Yoshino A, et al. Characterization of fat distribution in Prader-Willi syndrome: relationships with adipocytokines and influence of growth hormone treatment. Am J Med Genet A. 2013 Jan;161A(1):27–33. https://doi.org/10.1002/ajmg.a.35653.

  20. 20.

    Alsaif M, Elliot SA, MacKenzie ML, Prado CM, Field CJ, Haqq AM. Energy metabolism profile in individuals with Prader-Willi syndrome and implications for clinical management: a systematic review. Adv Nutr. 2017 Nov 15;8(6):905–15. https://doi.org/10.3945/an.117.016253.

  21. 21.

    Butler MG, Theodoro MF, Bittel DC, Donnelly JE. Energy expenditure and physical activity in Prader-Willi syndrome: comparison with obese subjects. Am J Med Genet A. 2007 Mar 1;143A(5):449–59.

  22. 22.

    Talebizadeh Z, Butler MG. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects. Clin Genet. 2005;67:230–9.

  23. 23.

    Marzullo P, Marcassa C, Minocci A, Campini R, Eleuteri E, Alessandro Gondoni L, et al. Long-term echocardiographic and cardioscintigraphic effects of growth hormone treatment in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2015 May;100(5):2106–14. https://doi.org/10.1210/jc.2015-1063.

  24. 24.

    Hedgeman E, Ulrichsen SP, Carter S, Kreher NC, Malobisky KP, Braun MM, et al. Long-term health outcomes in patients with Prader-Willi Syndrome: a nationwide cohort study in Denmark. Int J Obes. 2017 Oct;41(10):1531–8. https://doi.org/10.1038/ijo.2017.139.

  25. 25.

    Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N, et al. Deaths due to choking in Prader-Willi syndrome. Am J Med Genet A. 2007 Mar 1;143A(5):484–7.

  26. 26.

    Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2007;45(2):272–4.

  27. 27.

    Einfeld SL, Kavanagh SJ, Smith A, Evans EJ, Tonge BJ, Taffe J. Mortality in Prader-Willi syndrome. Am J Ment Retard. 2006 May;111(3):193–8.

  28. 28.

    Grugni G, Crinò A, Bosio L, et al. The Italian National Survey for Prader-Willi syndrome: an epidemiologic study. Am J Med Genet A. 2008;146:861–72.

  29. 29.

    Manzardo AM, Loker J, Heinemann J, Loker C, Butler MG. Survival trends from the Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2018 Jan;20(1):24–30. https://doi.org/10.1038/gim.2017.92.

  30. 30.

    Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2017 Jun;19(6):635–42. https://doi.org/10.1038/gim.2016.178.

  31. 31.

    Laurier V, Lapeyrade A, Copet P, Demeer G, Silvie M, Bieth E, et al. Medical, psychological and social features in a large cohort of adults with Prader-Willi syndrome: experience from a dedicated centre in France. J Intellect Disabil Res. 2015;59(5):411–21.

  32. 32.

    • Yang A, Kim J, Cho SY, Jin DK. Prevalence and risk factors for type 2 diabetes mellitus with Prader-Willi syndrome: a single center experience. Orphanet J Rare Dis. 2017;12(1):146. https://doi.org/10.1186/s13023-017-0702-5. This is the first study that identifies a high frequency of microvascular complications (24% of cases) in PWS patients with T2DM, which appear to be positively correlated with HOMA-IR and advanced age.

  33. 33.

    Anhalt H, Eckert KH, Hintz RL, Neely EK. Type I diabetes mellitus, ketoacidosis and thromboembolism in an adolescent with Prader-Willi syndrome. Acta Paediatr. 1996;85:516.

  34. 34.

    Bassali R, Hoffman WH, Chen H, Tuck-Muller CM. Hyperlipidemia, insulin-dependent diabetes mellitus, and rapidly progressive diabetic retinopathy and nephropathy in Prader-Willi syndrome with del(15)(q11.2q13). Am J Med Genet. 1997;71(3):267–70.

  35. 35.

    Bakker NE, Kuppens RJ, Siemensma EP, Tummers-de Lind van Wijngaarden RF, Festen DA, Bindels-de Heus GC, et al. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. J Clin Endocrinol Metab. 2013;98:4013–22.

  36. 36.

    Mariani B, Cammarata B, Grechi E, Di Candia S, Chiumello G. Maturity onset diabetes of the young in a child with Prader-Willi syndrome. Horm Res. 2012;78(suppl 1):162.

  37. 37.

    Bogova E, Shiryaeva T, Nagaeva E, Volevodz N, Peterkova V, Bezlepkina O. The “double diabetes” in adolescent with Prader-Willi syndrome. ESPE Abstracts. 2019;92:P1–356.

  38. 38.

    Schmidt F, Kapellen TM, Wiegand S, Herbst A, Wolf J, Fröhlich-Reiterer EE, et al. Holl RW; DPV-Wiss study group; BMBF competence network diabetes. Diabetes mellitus in children and adolescents with genetic syndromes. Exp Clin Endocrinol Diabetes. 2012;120(10):579–85.

  39. 39.

    Vogels A, Fryns JP. Age at diagnosis, body mass index and physical morbidity in children and adults with the Prader-Willi syndrome. Genet Couns. 2004;15(4):397–404.

  40. 40.

    Diene G, Mimoun E, Feigerlova E, Caula S, Molinas C, Grandjean H, et al. Endocrine disorders in children with Prader-Willi syndrome - data from 142 children of the French database. Horm Res Paediatr. 2010;74(2):121–8.

  41. 41.

    Sinnema M, Maaskant MA, van Schrojenstein Lantman-de Valk HM, van Nieuwpoort IC, Drent ML, Curfs LMG, et al. Physical health problems in adults with Prader–Willi syndrome. Am J Med Genet A. 2011;155:2112–24.

  42. 42.

    Sinnema M, Schrander-Stumpel CT, Maaskant MA, Boer H, Curfs LM. Aging in Prader-Willi syndrome: twelve persons over the age of 50 years. Am J Med Genet A. 2012;158A:1326–36.

  43. 43.

    Butler JV, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study. Dev Med Child Neurol. 2002;44:248–55.

  44. 44.

    Krochik AG, Ozuna B, Torrado M, Chertkoff L, Mazza C. Characterization of alterations in carbohydrate metabolism in children with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2006;19(7):911–8.

  45. 45.

    Lutski M, Zucker I, Zadik Z, Libruder C, Blumenfeld O, Shohat T, et al. Prevalence of diabetes among children treated with growth hormone in Israel. Diabet Med. 2019. https://doi.org/10.1111/dme.13910.

  46. 46.

    Tsuchiya T, Oto Y, Ayabe T, Obata K, Murakami N, Nagai T. Characterization of diabetes mellitus in Japanese Prader-Willi syndrome. Clin Pediatr Endocrinol. 2011;20:33–8.

  47. 47.

    Brambilla P, Crinò A, Bedogni G, Bosio L, Cappa M, Corrias A, et al. Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Metabolic syndrome in children with Prader-Willi syndrome: the effect of obesity. Nutr Metab Cardiovasc Dis. 2011;21:269–76.

  48. 48.

    Grugni G, Crinò A, Bedogni G, Cappa M, Sartorio A, Corrias A, et al. Metabolic syndrome in adult patients with Prader-Willi syndrome. Nutr Metab Cardiovasc Dis. 2013;23(11):1134–40.

  49. 49.

    •• Fintini D, Grugni G, Bocchini S, Brufani C, Di Candia S, Corrias A, et al. Genetic Obesity Study Group of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED). Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study. Nutr Metab Cardiovasc Dis. 2016;26(9):842–7. The results of this study show a high prevalence of glucose metabolism alterations in a large cohort of PWS patients, which appear to be more common in obese and adults subjects. The authors reported that impaired glucose metabolism during GH therapy in PWS could be mainly due to weight gain rather than to GH administration.

  50. 50.

    Zipf WB, Odorisio TM, Cataland S, Dixon K. Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome. J Clin Endocrinol Metab. 1983;57:1074–80.

  51. 51.

    Gumus Balikcioglu P, Balikcioglu M, Muehlbauer MJ, Purnell JQ, Broadhurst D, Freemark M, et al. Macronutrient Regulation of Ghrelin and Peptide YY in Pediatric Obesity and Prader-Willi Syndrome. J Clin Endocrinol Metab. 2015 Oct;100(10):3822–31. https://doi.org/10.1210/jc.2015-2503.

  52. 52.

    Schuster D, Osei K, Zipf WB. Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism. 1996;45(12):1514–20.

  53. 53.

    Haqq AM, Muelhlbauer M, Newgard CB, Grambow SC, Freemark MS. The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index. J Clin Endocrinol Metab. 2011;96:E225–32.

  54. 54.

    Lacroix D, Moutel S, Coupaye M, Huvenne H, Faucher P, Pelloux V, et al. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab. 2015;100(3):850–9.

  55. 55.

    Hoybye C, Hilding A, Jacobsson H, Thoren M. Metabolic profile and body composition in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2002;87:3590–7.

  56. 56.

    Goldstone AP, Holland AJ, Butler JV, Whittington JE. Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes. 2012;36(12):1564–70.

  57. 57.

    • Hirsch HJ, Gross I, Pollak Y, Eldar-Geva T, Gross-Tsur V. Irisin and the metabolic phenotype of adults with Prader-Willi syndrome. PLoS One. 2015;10(9):e0136864. https://doi.org/10.1371/journal.pone.0136864. This study highlights the peculiar metabolic phenotype of PWS compared to subjects with simple obesity and hypothesize that abnormal secretion or regulation of irisin activity may contribute to some of the metabolic features of PWS, including glucose metabolism.

  58. 58.

    Emerick JE, Vogt KS. Endocrine manifestations and management of Prader-Willi syndrome. Int J Pediatr Endocrinol. 2013;21:14.

  59. 59.

    Grugni G, Marzullo P. Diagnosis and treatment of GH deficiency in Prader-Willi syndrome. Best Pract Res Clin Endocrinol Metab. 2016;30(6):785–94.

  60. 60.

    Kuppens RJ, Diène G, Bakker NE, Molinas C, Faye S, Nicolino M, et al. Elevated ratio of acylated to unacylated ghrelin in children and young adults with Prader-Willi syndrome. Endocrine. 2015 Dec;50(3):633–42. https://doi.org/10.1007/s12020-015-0614-x.

  61. 61.

    Burnett LC, LeDuc CA, Sulsona CR, Paull D, Rausch R, Eddiry S, et al. Deficiency in prohormone convertase PC1 impairs prohormone processing in Prader-Willi syndrome. J Clin Invest. 2017;127(1):293–305.

  62. 62.

    Purtell S, Sze L, Loughnan G, Smith E, Herzog H, Sainsbury A, et al. In adults with Prader-Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels. Neuropeptides. 2011;45:301–7.

  63. 63.

    Shashaj B, Luciano R, Contoli B, Morino GS, Spreghini MR, Rustico C, et al. Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol. 2016;53(2):251–60.

  64. 64.

    Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS; 2011 Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants, GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013; 98:E1072–1087.

  65. 65.

    Crinò A, Di Giorgio G, Manco M, Grugni G, Maggioni A. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome. Horm Res. 2007;68:83–90.

  66. 66.

    Jørgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, et al. Glucose homeostasis in adults with Prader-Willi syndrome during treatment with growth hormone: results from a 12-month prospective study. Growth Hormon IGF Res. 2014;24(1):16–21.

  67. 67.

    Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis. Clin Endocrinol. 2012;77:86–93.

  68. 68.

    Höybye C. Growth hormone treatment of Prader-Willi syndrome has long-term, positive effects on body composition. Acta Paediatr. 2015;104(4):422–7.

  69. 69.

    L'Allemand D, Eiholzer U, Schlumpf M, Torresani T, Girard J. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome. Horm Res. 2003;59(5):239–48.

  70. 70.

    Coupaye M, Tauber M, Cuisset L, Laurier V, Bieth E, Lacorte JM, et al. Effect of genotype and previous GH treatment on adiposity in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2016;101(12):4895–903.

  71. 71.

    Basheer R, Jalal MJ, Gomez R. An unusual case of adolescent type 2 diabetes mellitus: Prader-Willi syndrome. J Family Med Prim Care. 2016;5(1):181–3.

  72. 72.

    American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care. 2019;42 (Suppl.1):S13-S28

  73. 73.

    Yigit S, Estrada E, Bucci K, Hyams J, Rosengren S. Diabetic ketoacidosis secondary to growth hormone treatment in a boy with Prader-Willi syndrome and steatohepatitis. J Pediatr Endocrinol Metab. 2004;17(3):361–4.

  74. 74.

    Hori H, Sato Y, Nakashima M. Prader-Willi syndrome case with proliferative diabetic retinopathy in both eyes treated by early vitrectomy under local anesthesia. Nippon Ganka Gakkai Zasshi. 2012 Feb;116(2):114–8.

  75. 75.

    McCandless SE. Committee on genetics. Clinical report-health supervision for children with Prader-Willi syndrome. Pediatrics. 2011 Jan;127(1):195–204. https://doi.org/10.1542/peds.2010-2820.

  76. 76.

    Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M. Speakers contributors at the second expert meeting of the comprehensive care of patients with PWS: recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab. 2008;93:4183–97.

  77. 77.

    Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61(12):2461–98. https://doi.org/10.1007/s00125-018-4729-5 Erratum in: Diabetologia. 2019 May;62(5):873.

  78. 78.

    Kousholt AM, Beck-Nielsen H, Lund HT. A reduced number of insulin receptors in patients with Prader-Willi syndrome. Acta Endocrinol. 1983;104(3):345–51.

  79. 79.

    Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs. 2003;63(18):1879–94.

  80. 80.

    Miller JL, Linville TD, Dykens EM. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: a pilot study. J Pediatr Endocrinol Metab. 2014;27(1–2):23–9.

  81. 81.

    Yamakita T, Ishii T, Mori T, Yoshioka K, Sato T, Tanaka S, et al. Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. Diabetes Res Clin Pract. 1998;42(3):205–8.

  82. 82.

    Seetho IW, Jones G, Thomson GA, Fernando DJ. Treating diabetes mellitus in Prader-Willi syndrome with Exenatide. Diabetes Res Clin Pract. 2011 Apr;92(1):e1–2. https://doi.org/10.1016/j.diabres.2010.12.009.

  83. 83.

    Cyganek K, Koblik T, Kozek E, Wojcik M, Starzyk J, Malecki MT. Liraglutide therapy in Prader-Willi syndrome. Diabet Med. 2011;28(6):755–6.

  84. 84.

    Sze L, Purtell L, Jenkins A, Loughnan G, Smith E, Herzog H, et al. Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. J Clin Endocrinol Metab. 2011;96(8):E1314–9. https://doi.org/10.1210/jc.2011-0038.

  85. 85.

    Senda M, Ogawa S, Nako K, Okamura M, Sakamoto T, Ito S. The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome. Endocr J. 2012;59(10):889–94.

  86. 86.

    Cadena-Obando DA, Molina-Ayala MA, Ferreira-Hermosillo A. Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report. Nutr Hosp. 2018;35(3):743–6. https://doi.org/10.20960/nh.1525.

  87. 87.

    Fintini D, Grugni G, Brufani C, Bocchini S, Cappa M, Crinò A. Use of GLP-1 receptor agonists in Prader-Willi syndrome: report of six cases. Diabetes Care. 2014;37:e76–7. https://doi.org/10.2337/dc13-2575.

  88. 88.

    Arenz T, Schwarzer A, Pfluger T, Koletzko S, Schmidt H. Delayed gastric emptying in patients with PraderWilli syndrome. J Pediatr Endocrinol Metab. 2010;23(9):867–71.

  89. 89.

    Hauber M, Stratmann B, Hoedebeck-Stuntebeck N, Tschoepe D. Medical management for adults with Prader-Willi syndrome. Metab Syndr Relat Disord. 2013;11(6):392–6.

  90. 90.

    Kato E, Kimura M, Okuda T, Toyoda M, Fukagawa M. Behavior modification maintenance with long-term blood glucose and weight management in Prader-Willi syndrome complicated with diabetes: team management approach combined with pharmacological treatment. Case Rep Med. 2019;19:1–7. https://doi.org/10.1155/2019/6129019.

  91. 91.

    Fong AK, Wong SK, Lam CC, Ng EK. Ghrelin level and weight loss after laparoscopic sleeve gastrectomy and gastric mini-bypass for Prader-Willi syndrome in Chinese. Obes Surg. 2012;22(11):1742–5.

  92. 92.

    Alqahtani AR, Elahmedi MO, Al Qahtani AR, Lee J, Butler MG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg Obes Relat Dis. 2016 Jan;12(1):100–10. https://doi.org/10.1016/j.soard.2015.07.014.

  93. 93.

    Papavramidis ST, Kotidis EV, Gamvros O. Prader-Willi syndrome-associated obesity treated by biliopancreatic diversion with duodenal switch. Case report and literature review. J Pediatr Surg. 2006 Jun;41(6):1153–8.

  94. 94.

    Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2008;46(1):80–3.

  95. 95.

    Liu SY, Wong SK, Lam CC, Ng EK. Bariatric surgery for Prader-Willi syndrome was ineffective in producing sustainable weight loss: long term results for up to 10 years. Pediatr Obes. 2020; 15(1):e12575 https://doi.org/10.1111/ijpo.12575.

  96. 96.

    Azim S, Kashyap SR. Bariatric surgery: pathophysiology and outcomes. Endocrinol Metab Clin N Am. 2016 Dec;45(4):905–21. https://doi.org/10.1016/j.ecl.2016.06.011.

  97. 97.

    Yu H, Di J, Jia W. Laparoscopic sleeve gastrectomy in Chinese female patient with Prader-Willi syndrome and diabetes. Surg Obes Relat Dis. 2013;9(2):e25–7. https://doi.org/10.1016/j.soard.2012.07.009.

  98. 98.

    Cazzo E, Gestic MA, Utrini MP, Chaim FDM, Cândido EC, Jarolavsky LBDS, et al. Bariatric surgery in individuals with severe cognitive impairment: report of two cases. Sao Paulo Med J. 2018;6(1):84–8. https://doi.org/10.1590/1516-3180.2016.0299071216.

Download references

Author information

Correspondence to Antonino Crinò.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Other Forms of Diabetes and Its Complications

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Crinò, A., Grugni, G. Update on Diabetes Mellitus and Glucose Metabolism Alterations in Prader-Willi Syndrome. Curr Diab Rep 20, 7 (2020). https://doi.org/10.1007/s11892-020-1284-5

Download citation

Keywords

  • Prader-Willi syndrome
  • Diabetes mellitus
  • Impaired glucose tolerance
  • Hyperglycemia